A study to investigate NPS and symptoms in Chinese adult participants with CRSwNP initiating treatment with tezepelumab

Trial Identifier:	D5242L00001
Sponsor:	AstraZeneca
Start Date:	April 2026
Primary Completion Date:	March 2028
Study Completion Date:	March 2028
Condition:	Nose and Sinus Disorder

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Stay informed about new Trial Results Summaries with our email notification service

Trial Locations

Country	Location
CN	Beijing, CN, 100730

Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered office is 3 More London Riverside, London SE1 2AQ.